Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 19, 2007
- Shionogi: Crestor Increases Profits with Royalty Income
November 19, 2007
- Prasugrel Reduces Risk of Serious CV Events by 19%: AHA
November 19, 2007
- Global Pharma Market to Grow 5-6% in 2008: IMS Health
November 19, 2007
- R&D NEWS IN BRIEF
November 19, 2007
- BUSINESS NEWS IN BRIEF
November 19, 2007
- Generics Dispensed for 1.4% of Prescriptions Permitting Substitution: Korosho Survey
November 19, 2007
- NEW PRODUCTS
November 19, 2007
- GENERICS NEWS IN BRIEF
November 19, 2007
- Council to Recommend Reductions in Medical Fees, NHI Drug Prices
November 19, 2007
- Korosho to Determine Information Needed When Selling OTC Drugs
November 19, 2007
- New IDF DM Management GL Stresses Importance of Postprandial Glucose
November 19, 2007
- Education on Vaccination for Uterine Cervical Cancer Needed
November 19, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 19, 2007
- Daiichi Sankyo to File Applications for Prasugrel in US, Europe
November 19, 2007
- Operating Profits Up for All 9 Leading Domestic Companies
November 19, 2007
- Takeda: Overseas Sales Exceed 50% Driven by Actos
November 19, 2007
- Astellas: Overseas Sales Exceed 50% of Total Sales
November 19, 2007
- DSP: 4 Strategic Products Show Strong Sales
November 19, 2007
- Taisho: Stock Levels Normalized
November 19, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…